Jan. 26, 2011 (Baystreet.ca) --
Palm Beach, FL -- Today Free Biotech Stock Alert (http://www.FreeBiotechStockAlert.com), a leading penny stock / small-cap information site, is highlighting Neurokine Pharmaceuticals (OTCBB:NEUKF), Corcept Therapeutics (CORT), Arena Pharmaceuticals (ARNA) and Orexigen Therapeutics (OREX). Neurokine Pharmaceuticals (OTCBB:NEUKF)
The company recently announced the completion of its new clinical trials plan to test the effects of NK-001 in the treatment of Alzheimer's type memory loss in patients undergoing coronary artery bypass graft (CABG) surgery. The plan will be to carry out clinical trials in 50 patients following CABG surgery and to test these patients for up to 12 months following surgery for cognitive impairment (similar to Alzheimer's). The patients will be divided in 2 groups; 25 will receive NK-001 and 25 will receive placebo. The clinical trials will be carried out in 4 to 6 sites with cardiosurgery and psychiatry expertise in Europe and expected to complete within 12 to 18 months. The company expects to finalize site selection and contract with its designated clinical investigation group in the next 4 to 6 weeks. "We are extremely pleased with the completion of our new clinical trials plan. This is a milestone achievement for Neurokine as we look forward to the completion of our proposed Phase II trial plans," said Ahmad Doroudian, President and CEO of Neurokine. Neurokine is developing proprietary encapsulation technology to allow better blood brain barrier penetration to initiate and enhance therapeutic effects of anti-inflammatory drugs in the treatment of neurodegenerative diseases.
Corcept Therapeutics (CORT)
Corcept is a pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders. Arena Pharmaceuticals (ARNA)
Arena Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops innovative therapies offering medical advances and new options for patients. Orexigen Therapeutics (OREX)
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. At Free Biotech Stock Alert we know that nothing speaks louder than our picks and the success of our subscribers! In today's markets, investors need to be in the know. Knowledge is more than power, its money. That's why our team at Free Biotech Stock Alert tracks the hottest stocks all over the biotech market in order to keep our subscribers tuned in. We focus mainly on microcap, small cap and penny stock companies - companies that allow our investors to bring home big profits. We work diligently and provide all investors - large or small - an opportunity to track stocks with the potential to make big gains. Join our FREE newsletter today and receive our report coming out next week.
While many of the other investment newsletters talk a big game, at Free Biotech Stock Alert we let our research do the talking!
Disclaimer: Free Biotech Stock Alert is not a registered investment advisor. Investors are responsible for doing their own research and obtaining professional investment advice. Free Biotech Stock Alert does not guarantee the accurateness of information in its communications. Investors should read the full disclaimer at www.FreeBiotechStockAlert.com before investing in any stock featured by the site. Free Biotech Stock Alert is a division of Cooperman Bros. For more information, please contact:
www.FreeBiotechStockAlert.com
Editor
(888) 790-9777
info@FreeBiotechStockAlert.com